Our in silico analysis identified the cyclin-dependent kinase inhibitor 1a (CDKN1A, also known as p21) as a gene of future interest, as it links the gene panels of “ROS”, “insulin resistance” and “mammary adenocarcinoma”. This evidence concerns the gene INS and breast adenocarcinoma.